Results 291 to 300 of about 1,341,296 (383)

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study. [PDF]

Support Care Cancer
Detlefsen SS, Andersen DS, Knudsen AØ, Nøttrup TJ, Möller S, Nyvang GB, Jørgensen TL, Herrstedt J, Ruhlmann CH.   +8 more
europepmc   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

125I inhibits the progression of cervical cancer by upregulating the HSF1/PU.1/SYK signaling pathway and consequently enhancing the apoptotic response mediated by ROS/USP7/P53. [PDF]

Sci Rep
Fan X, Liang X, Guo Y, Jin G, Ming D, An X.   +5 more
europepmc   +1 more source

Chemotherapy with Preoperative Radiotherapy in Rectal Cancer

, 2007
J. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, L. Radošević-Jelić, A. Daban, É. Bardet, A. Beny, J. Ollier   +9 more
semanticscholar   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

A prognostic model for head and neck squamous cell carcinoma based on radiotherapy sensitivity insights from nasopharyngeal carcinoma. [PDF]

Discov Oncol
Fei Y, Liu Z, Yuan J, Qiu L, Zhu Y, Shi K, Luo J, Wu M, Xu W, Zhou S.   +9 more
europepmc   +1 more source

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

FEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa, Ilva Liekniņa, Svetlana Koteloviča, Ramona Petrovska, Gediminas Žvinys, Agne Petrosiute, Asta Zubrienė, Matīss Toms Laugalis, Vendija Skeltona, Juris Jansons, Madara Kreishmane, Edita Čapkauskaitė, Daumantas Matulis, Kaspars Tārs   +13 more
wiley   +1 more source